Repros Therapeutics Inc.
Repros Therapeutics Announces Amendment of NIH Proellex(R) License
Published in Biotech Business Week, November 9th, 2009
Repros Therapeutics (NasdaqGM:RPRX) announced that the Company has entered into an amendment with the National Institutes of Health (NIH) to its existing exclusive license for Proellex® that revises the existing milestones and dates for performance to provide additional time to lift the current clinical hold on Proellex or select a second generation molecule for further development from the family of anti-progestational agents covered by the license.
Previously the Company announced in early August 2009 that it had voluntarily suspended dosing of all patients in its Proellex clinical trials. The FDA subsequently notified Repros that the Proellex program was placed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- BioMed Central
Epilepsy drugs could treat Alzheimer's and Parkinson's - BioMed Central
Genes that drive you to drink but don't make you an alcoholic - BioMed Central
Nepotism has its benefits when it comes to survival - BioMed Central
Pain thresholds linked to inflammation and sleep problems in arthritis patients - Cell Transplantation Center of Excellence for Aging and Brain Repair
Placental precursor stem cells require testosterone-free environment to survive - Elsevier Health Sciences
Study shows hormone replacement therapy decreases mortality in younger postmenopausal woman - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
